We further evaluated whether addition of CDK2i to CDK4/6i and fulvestrant could inhibit cell growth of combined CDK4/6i and fulvestrant-resistant ER+ BC cells that exhibited high expression of CDK6, p-CDK2 and/or cyclin E1. This evidence concerns the gene CDK4 and breast cancer.